Stock Yards Bank & Trust Co. Sells 3,520 Shares of Astrazeneca Plc $AZN

Posted by Brian Himes on Jul 3rd, 2026

Stock Yards Bank & Trust Co. decreased its stake in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 49.5% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,594 shares of the company’s stock after selling 3,520 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Astrazeneca were worth $709,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in AZN. Bank of America Corp DE grew its stake in shares of Astrazeneca by 4.7% in the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after buying an additional 1,461,786 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Astrazeneca by 2.1% in the fourth quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock valued at $3,791,051,000 after acquiring an additional 438,709 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Astrazeneca by 2.3% in the 4th quarter. Franklin Resources Inc. now owns 20,157,744 shares of the company’s stock valued at $3,537,684,000 after acquiring an additional 445,014 shares during the period. Morgan Stanley grew its position in shares of Astrazeneca by 3.2% in the 4th quarter. Morgan Stanley now owns 13,878,726 shares of the company’s stock valued at $2,435,716,000 after acquiring an additional 432,939 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Astrazeneca by 9.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock worth $521,517,000 after purchasing an additional 582,183 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Trading Up 6.0%

Shares of Astrazeneca stock opened at $194.96 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The firm has a 50-day moving average of $183.91 and a 200-day moving average of $187.76. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71. The stock has a market cap of $302.36 billion, a PE ratio of 29.27, a PEG ratio of 1.49 and a beta of 0.24.

Astrazeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. As a group, sell-side analysts forecast that Astrazeneca Plc will post 10.28 EPS for the current year.

Key Stories Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.

Analysts Set New Price Targets

AZN has been the subject of several recent analyst reports. Barclays reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research note on Tuesday. Weiss Ratings cut Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 18th. Finally, Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Fourteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $205.33.

View Our Latest Stock Report on AZN

Astrazeneca Company Profile

(Free Report)

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.